EUVIMEDEUVIMED entdecken
Crossref

De Novo Design of Structure‐Tunable Multivalent Targeting Chimeras for Tumor‐Targeted PD‐L1 Degradation and Potentiated Cancer Immunotherapy

Huiling Zhou, Bo Hou, Yiming Shan, Lujia Huang, Fangmin Chen, Siyuan Ren, Shunan Zhang, Jiaxing Pan, Yijing Dang, Haijun Yu, Zhiai Xu

Angewandte Chemie International Edition · 2025-07 · 64 (27)

DOI: 10.1002/anie.202504233 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Angewandte Chemie International Edition, online erschienen am 05.05.2025. Verfasst von Huiling Zhou und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200241, China. Hauptthemen laut MEDLINE: B7-H1 Antigen, Immunotherapy, Drug Design, Antineoplastic Agents. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 43 Literaturangaben. Gefördert von: Science and Technology Commission of Shanghai Municipality, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Targeted protein degradation (TPD) technology holds significant potential for modulating protein homeostasis and treating diseases. However, current methods for degrading membrane proteins highly depend on the lysosome‐targeting ligands or membrane receptors. In this study, we present a set of multivalent targeting chimeras (multi‐TACs) for tumor‐specific degradation of programmed death ligand 1 (PD‐L1) on the surface of the tumor cell membrane. The multi‐TACs are synthesized by copolymerization of small‐molecule PD‐L1 inhibitor BMS‐1 with acid‐responsive monomers. The chemical structures of the multi‐TACs are optimized by investigating the correlation between PD‐L1 degradation efficacy and the key parameters, including acid‐sensitive moieties, BMS‐1 valency, and spacer length. Mechanistic study reveals that the multi‐TACs highly efficiently degrade PD‐L1 on the surface of tumor cells via the adsorption‐mediated endocytosis and lysosomal degradation pathways, which differ from the reported strategies for membrane protein degradation. The outperformed multi‐TAC GG56 with tumor extracellular acidity and enzyme‐sensitivity dramatically reduces PD‐L1 levels and suppresses tumor growth in mouse models of B16‐F10 melanoma and 4T1 breast tumors. Furthermore, GG56 serves as a versatile nanoplatform for combinatory chemo‐immunotherapy and radio‐immunotherapy of 4T1 breast tumor by co‐delivery of chemotherapeutic and radio‐sensitizer, respectively.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

B7-H1 AntigenImmunotherapyDrug DesignAntineoplastic AgentsNeoplasmsHumansAnimalsMiceMolecular StructureProteolysisCell Line, TumorFemale

Stichwörter der Autor:innen

Combinatory therapy, Immune checkpoint blockade, Multivalent targeting chimerasTumor microenvironmentTumor‐specific PD‐L1 degradation

Substanzen

B7-H1 AntigenCD274 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • School of Chemistry and Molecular Engineering, East China Normal University, Shanghai, 200241, China.
  • State Key Laboratory of Chemical Biology and Center of Pharmaceutics, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, 201203, China.
  • Yantai Key Laboratory of Nanomedicine & Advanced Preparations, Yantai Institute of Materia Medica, Shandong, 264000, China.
  • University of Chinese Academy of Sciences, Beijing, 100049, China.

Förderung

  • Science and Technology Commission of Shanghai Municipality
  • National Natural Science Foundation of China

Zitieren

APA

Zhou, H., Hou, B., Shan, Y., Huang, L., Chen, F., Ren, S., Zhang, S., Pan, J., Dang, Y., Yu, H., & Xu, Z. (2025). De Novo Design of Structure‐Tunable Multivalent Targeting Chimeras for Tumor‐Targeted PD‐L1 Degradation and Potentiated Cancer Immunotherapy. Angewandte Chemie International Edition, 64(27). https://doi.org/10.1002/anie.202504233

Vancouver

Zhou H, Hou B, Shan Y, Huang L, Chen F, Ren S, et al. De Novo Design of Structure‐Tunable Multivalent Targeting Chimeras for Tumor‐Targeted PD‐L1 Degradation and Potentiated Cancer Immunotherapy. Angewandte Chemie International Edition. 2025;64(27). doi:10.1002/anie.202504233

BibTeX
@article{Zhou2025,
  author = {Zhou, Huiling and Hou, Bo and Shan, Yiming and Huang, Lujia and Chen, Fangmin and Ren, Siyuan and Zhang, Shunan and Pan, Jiaxing and Dang, Yijing and Yu, Haijun and Xu, Zhiai},
  title = {De Novo Design of Structure‐Tunable Multivalent Targeting Chimeras for Tumor‐Targeted PD‐L1 Degradation and Potentiated Cancer Immunotherapy},
  journal = {Angewandte Chemie International Edition},
  year = {2025},
  volume = {64},
  number = {27},
  doi = {10.1002/anie.202504233}
}
Kostenlos starten →